• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例伴有脑转移的肾细胞癌患者的长期生存：病例报告

Long-term Survival in a Case of Renal Cell Carcinoma With Brain Metastases: A Case Report.

作者信息

Pooleri Ginil Kumar, Kleetus Jeeva Maria, Laddha Abhishek, Thomas Appu

机构信息

Department of Urology, Amrita Institute of Medical Sciences and Research Centre, Kochi, India.

出版信息

Clin Med Insights Case Rep. 2019 Jun 20;12:1179547619854703. doi: 10.1177/1179547619854703. eCollection 2019.

DOI:10.1177/1179547619854703
PMID:31258340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6587384/
Abstract

Renal cell carcinoma with brain metastases is considered to have a poor prognosis. We are reporting a case of a 63-year-old male who showed excellent long term remission with a combination treatment of radiation and tyrosine kinase inhibitor for a solitary lesion in the brain, secondary to the renal tumor.

摘要

伴有脑转移的肾细胞癌被认为预后较差。我们报告一例63岁男性患者，其因肾肿瘤继发脑部孤立性病灶，经放疗和酪氨酸激酶抑制剂联合治疗后获得了长期良好缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be97/6587384/81ce8aa9cc83/10.1177_1179547619854703-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be97/6587384/0f42c254b5ca/10.1177_1179547619854703-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be97/6587384/81ce8aa9cc83/10.1177_1179547619854703-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be97/6587384/0f42c254b5ca/10.1177_1179547619854703-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be97/6587384/81ce8aa9cc83/10.1177_1179547619854703-fig2.jpg

相似文献

1
Long-term Survival in a Case of Renal Cell Carcinoma With Brain Metastases: A Case Report.一例伴有脑转移的肾细胞癌患者的长期生存：病例报告
Clin Med Insights Case Rep. 2019 Jun 20;12:1179547619854703. doi: 10.1177/1179547619854703. eCollection 2019.
2
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.卡博替尼在肾细胞癌放射性耐药脑转移瘤中的活性：两例报告
J Med Case Rep. 2018 Nov 25;12(1):351. doi: 10.1186/s13256-018-1875-9.
3
The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.肾上腺切除术对原发性肾细胞癌孤立性转移扩散病例的治疗价值。
Eur Urol. 2005 Aug;48(2):252-7. doi: 10.1016/j.eururo.2005.04.004. Epub 2005 Apr 21.
4
Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report.转移性肉瘤样肾细胞癌多学科治疗后的长期生存：一例报告
J Med Case Rep. 2015 Nov 19;9:261. doi: 10.1186/s13256-015-0751-0.
5
Long-term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation.
Cancer. 1993 Feb 15;71(4):1353-61. doi: 10.1002/1097-0142(19930215)71:4<1353::aid-cncr2820710430>3.0.co;2-6.
6
Extremely Delayed Multiple Brain Metastases from Renal Cell Carcinoma: Remission Achieved with Total Surgical Removal: Case Report and Literature Review.肾细胞癌导致的极晚期多发性脑转移：通过手术全切实现缓解：病例报告及文献综述
World Neurosurg. 2016 Aug;92:583.e13-583.e17. doi: 10.1016/j.wneu.2016.05.065. Epub 2016 May 30.
7
Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.肾细胞癌脑转移患者的放射外科治疗：长期疗效及影响生存和局部肿瘤控制的预后因素
J Neurosurg. 2003 Feb;98(2):342-9. doi: 10.3171/jns.2003.98.2.0342.
8
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.转移性肾细胞癌转移至胰腺时酪氨酸激酶抑制剂舒尼替尼何时可停用：一例报告
J Med Case Rep. 2018 Mar 20;12(1):80. doi: 10.1186/s13256-018-1597-z.
9
Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.肾细胞癌脑转移患者生存的预后因素。
Cancer. 1998 Dec 15;83(12):2548-53.
10
Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.仑伐替尼联合放射性碘治疗晚期分化型甲状腺癌：病例报告及文献复习。
World J Surg Oncol. 2019 May 19;17(1):84. doi: 10.1186/s12957-019-1626-4.

引用本文的文献

1
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.纳武利尤单抗联合伊匹单抗治疗伴脑转移的晚期肾细胞癌患者的安全性和疗效：CheckMate 920 研究。
Cancer. 2022 Mar 1;128(5):966-974. doi: 10.1002/cncr.34016. Epub 2021 Nov 16.
2
Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma.酪氨酸激酶抑制剂（TKIs）联合放射治疗对肾细胞癌脑转移瘤治疗的影响
Front Oncol. 2020 Jul 23;10:1246. doi: 10.3389/fonc.2020.01246. eCollection 2020.

本文引用的文献

1
Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy.靶向治疗时代肾细胞癌脑转移瘤的多模态治疗
Ther Adv Med Oncol. 2016 Nov;8(6):450-459. doi: 10.1177/1758834016659825. Epub 2016 Jul 25.
2
Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression.肾癌患者的脑转移：转移模式、肿瘤相关巨噬细胞和趋化因子/趋化受体表达。
Br J Cancer. 2014 Feb 4;110(3):686-94. doi: 10.1038/bjc.2013.755. Epub 2013 Dec 10.
3
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
肾细胞癌酪氨酸激酶抑制剂时代的脑转移。
Clin Genitourin Cancer. 2013 Jun;11(2):155-60. doi: 10.1016/j.clgc.2012.11.001. Epub 2012 Dec 21.
4
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.肾细胞癌脑转移：临床表现、复发及生存情况
Cancer. 2008 Oct 1;113(7):1641-8. doi: 10.1002/cncr.23769.
5
Brain metastasis in renal cell cancer responding to sunitinib.肾细胞癌脑转移对舒尼替尼有反应。
Anticancer Res. 2007 Nov-Dec;27(6C):4255-7.
6
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.替西罗莫司、干扰素α或两者联合用于晚期肾细胞癌。
N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.
7
Sorafenib in advanced clear-cell renal-cell carcinoma.索拉非尼治疗晚期透明细胞肾细胞癌
N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655.
8
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.